A Second Drug Binding Site in P2X3

Trung Thach,KanagaVijayan Dhanabalan,Prajwal Prabhakarrao Nandekar,Seth Stauffer,Iring Heisler,Sarah Alvarado,Jonathan Snyder,Ramaswamy Subramanian

DOI: https://doi.org/10.1101/2024.06.10.598171

2024-06-14

Abstract:Purinergic P2X3 receptors form trimeric cation-gated channels, which are activated by extracellular ATP. P2X3 plays a crucial role in chronic cough and affects over 10% of the population. Despite considerable efforts to develop drugs targeting P2X3, the highly conserved structure within the P2X receptor family presents obstacles for achieving selectivity. Camlipixant, a potent and selective P2X3 antagonist, is currently in phase III clinical trials. However, the mechanisms underlying receptor desensitization, ion permeation, principles governing antagonism, and the structure of P2X3 when bound to camlipixant remain elusive. In this study, we established a stable cell line expressing homotrimeric P2X3 and utilized a peptide scaffold to purify the complex and determine its structure using cryo-electron microscopy (cryo-EM). P2X3 binds to camlipixant at a previously unidentified drug-binding site and functions as an allosteric inhibitor. Structure-activity studies combined with modeling and simulations have shed light on the mechanisms underlying the selective targeting and inhibition of P2X3 by camlipixant, distinguishing it from other members of the P2X receptor family.

Biochemistry

What problem does this paper attempt to address?

The key problem that this paper attempts to solve is how to understand and reveal the structural basis of the binding of the P2X3 receptor to the drug camlipixant and its mechanism of action. Specifically, the research aims to:

1. **Determine the binding site of camlipixant**: By using single - particle cryo - electron microscopy (cryo - EM) technology, the high - resolution structure of the P2X3 receptor in the camlipixant - bound state was resolved, and a previously unrecognized drug - binding site was discovered.

2. **Elucidate the mechanism of selective inhibition**: Explain why camlipixant can specifically target the P2X3 receptor rather than other P2X family members (such as P2X2/3), which is crucial for the development of highly effective drugs with few side effects for diseases such as chronic cough.

3. **Explore the regulation of receptor function**: Study how camlipixant affects the function of the P2X3 receptor through its unique binding mode, including preventing ATP binding, inhibiting ion channel opening, and stabilizing the receptor in a non - activated state.

4. **Provide structural biology support**: Provide detailed molecular - level information for future drug design, especially on how to optimize drugs to improve their selectivity and potency for specific receptors.

Through these efforts, researchers hope not only to deepen the understanding of the working mechanism of the P2X3 receptor but also to pave the way for the development of more effective therapeutic drugs. The following are some of the key formulas and structural features mentioned in the article:

- Changes in the ATP - binding site:
\[
V_{\text{ATP pocket}}^{\text{apo}} = 1161 \, \text{Å}^3 \quad \text{vs} \quad V_{\text{ATP pocket}}^{\text{camlipixant - bound}} = 573 \, \text{Å}^3
\]

- Changes in the volume of the camlipixant - binding pocket:
\[
V_{\text{camlipixant pocket}}^{\text{apo}} = 513 \, \text{Å}^3 \quad \text{vs} \quad V_{\text{camlipixant pocket}}^{\text{camlipixant - bound}} = 1203 \, \text{Å}^3
\]

These data indicate that camlipixant significantly changes the conformation of the P2X3 receptor after binding, thereby affecting its function.